- To read more about “Glutaryl-CoA dehydrogenase deficiency”
- Genet Med . 2021 Jan;23(1):13-21.
(source: OrphaNews 10 May 2021)
Glutaryl-CoA dehydrogenase deficiency : a study showed that newborn screening programs for Glutaric aciduria type 1 have an overall positive effect on the neurological outcome but their success depends on the quality of therapy
Related news
Steps since the 2021 UN Resolution on Rare Diseases: A review
Last month marks a year since the adoption in December 2021 of the UN ...
40 Years of the USA’s Orphan Drug Act: NORD takes stock
This month, the National Organization for Rare Disorders (NORD) is joi...
Universal neonatal screening for Sickle Cell Disease in France
The Haute Autorité de la Santé in France recently recommended to swi...
Together4RD launches policy asks at European Parliament
On 10 November 2022, Together4RD organised an event at the European Pa...
An optimal approach to rare disease management based on national experiences in Europe, North America and East Asia
A new study has been published in the Rare Diseases and Orphan Drugs J...
Michigan to destroy leftover blood samples it took from newborns
The state of Michigan has agreed to destroy more than 3 million dried ...